These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34365450)

  • 21. Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study.
    Adir Y; Hakrush O; Shteinberg M; Schneer S; Agusti A
    ERJ Open Res; 2018 Jul; 4(3):. PubMed ID: 30083552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori.
    Ra SW; Sze MA; Lee EC; Tam S; Oh Y; Fishbane N; Criner GJ; Woodruff PG; Lazarus SC; Albert R; Connett JE; Han MK; Martinez FJ; Aaron SD; Reed RM; Man SFP; Sin DD;
    Respir Res; 2017 May; 18(1):109. PubMed ID: 28558695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hospitalizations due to exacerbations of COPD: A big data perspective.
    Serra-Picamal X; Roman R; Escarrabill J; García-Altés A; Argimón JM; Soler N; Faner R; Carbonell EM; Trilla A; Agusti A
    Respir Med; 2018 Dec; 145():219-225. PubMed ID: 29398283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefit-harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease.
    Ahmadian S; Sin DD; Lynd L; Harrison M; Sadatsafavi M
    Thorax; 2022 Nov; 77(11):1079-1087. PubMed ID: 34836921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy.
    Han MK; Tayob N; Murray S; Dransfield MT; Washko G; Scanlon PD; Criner GJ; Casaburi R; Connett J; Lazarus SC; Albert R; Woodruff P; Martinez FJ
    Am J Respir Crit Care Med; 2014 Jun; 189(12):1503-8. PubMed ID: 24779680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azithromycin for prevention of exacerbations of COPD.
    Albert RK; Connett J; Bailey WC; Casaburi R; Cooper JA; Criner GJ; Curtis JL; Dransfield MT; Han MK; Lazarus SC; Make B; Marchetti N; Martinez FJ; Madinger NE; McEvoy C; Niewoehner DE; Porsasz J; Price CS; Reilly J; Scanlon PD; Sciurba FC; Scharf SM; Washko GR; Woodruff PG; Anthonisen NR;
    N Engl J Med; 2011 Aug; 365(8):689-98. PubMed ID: 21864166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study.
    Ichinose M; Nishimura M; Akimoto M; Kurotori Y; Zhao Y; de la Hoz A; Mishima M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2147-2156. PubMed ID: 30034230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pneumonia as comorbidity in chronic obstructive pulmonary disease (COPD). Differences between acute exacerbation of COPD and pneumonia in patients with COPD.
    Boixeda R; Bacca S; Elias L; Capdevila JA; Vilà X; Mauri M; Almirall J
    Arch Bronconeumol; 2014 Dec; 50(12):514-20. PubMed ID: 25443591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact.
    MacLeod M; Papi A; Contoli M; Beghé B; Celli BR; Wedzicha JA; Fabbri LM
    Respirology; 2021 Jun; 26(6):532-551. PubMed ID: 33893708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Balance and Falls in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Prospective Study.
    Oliveira CC; Lee AL; McGinley J; Anderson GP; Clark RA; Thompson M; Clarke S; Baker T; Irving LB; Denehy L
    COPD; 2017 Oct; 14(5):518-525. PubMed ID: 28745525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Azithromycin during Acute Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization (BACE). A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial.
    Vermeersch K; Gabrovska M; Aumann J; Demedts IK; Corhay JL; Marchand E; Slabbynck H; Haenebalcke C; Haerens M; Hanon S; Jordens P; Peché R; Fremault A; Lauwerier T; Delporte A; Vandenberk B; Willems R; Everaerts S; Belmans A; Bogaerts K; Verleden GM; Troosters T; Ninane V; Brusselle GG; Janssens W
    Am J Respir Crit Care Med; 2019 Oct; 200(7):857-868. PubMed ID: 31046405
    [No Abstract]   [Full Text] [Related]  

  • 36. Proton pump inhibitors for chronic obstructive pulmonary disease.
    Kikuchi S; Imai H; Tani Y; Tajiri T; Watanabe N
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013113. PubMed ID: 32844430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis.
    Cui Y; Luo L; Li C; Chen P; Chen Y
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3813-3829. PubMed ID: 30538443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of changes in physical activity on frequency of hospitalization in chronic obstructive pulmonary disease.
    Esteban C; Arostegui I; Aburto M; Moraza J; Quintana JM; Aizpiri S; Basualdo LV; Capelastegui A
    Respirology; 2014 Apr; 19(3):330-8. PubMed ID: 24483954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stability of Frequent Exacerbator Phenotype in Patients with Chronic Obstructive Pulmonary Disease.
    Krachunov I; Kyuchukov N; Ivanova Z; Yanev NA; Hristova PA; Pavlov P; Glogovska P; Popova T; Ivanov YY
    Folia Med (Plovdiv); 2018 Dec; 60(4):536-545. PubMed ID: 31188775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preventing COPD exacerbations with macrolides: a review and budget impact analysis.
    Simoens S; Laekeman G; Decramer M
    Respir Med; 2013 May; 107(5):637-48. PubMed ID: 23352223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.